Lung Cancer News and Research

Latest Lung Cancer News and Research

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ResponseDX: Lung genetic test panel to detect the presence of EML4-ALK gene variants in lung cancer patients. EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer.

1 Jul 2010

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.

30 Jun 2010

New approach to lung cancer measurement holds promise for smokers

The pilot program for Lung Cancer Alliance's (LCA) website for patient donated scans is helping open the door to a potentially new method for evaluating lung cancer risk in smokers as well as non-smokers.

30 Jun 2010

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Mirna Therapeutics announced today publication of new results in the journal Cancer Research demonstrating proof of concept that the systemic delivery of tumor suppressor microRNAs (miRNA) inhibits tumor growth by restoring the proper regulatory pathways required for cell cycle arrest and apoptosis.

30 Jun 2010

Guidance on ways to protect protect unborn babies from secondhand smoke exposure

New guidance from the National Institute for Health and Clinical Excellence (NICE) suggests that testing pregnant mothers would help to ensure they receive appropriate support they need to quit for good or reduce their exposure to secondhand smoke.

30 Jun 2010

Smoking bans in two Minnesota cities not associated with significant economic impact

The passage of smoking bans in two large Minnesota cities was not associated with job losses at bars and may in fact have contributed to higher employment in restaurants, according to new research.

30 Jun 2010

Asbestos induces cell necrosis, promotes tumor growth

More than 20 million people in the U.S., and many more worldwide, who have been exposed to asbestos are at risk of developing mesothelioma, a malignant cancer of the membranes that cover the lungs and abdomen that is resistant to current therapies.

30 Jun 2010

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

29 Jun 2010

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.

29 Jun 2010

Getting rid of asbestos in Australia

Asbestos that is linked to lung cancer called mesothelioma, is still present in more than one million Australian homes, offices and schools according to reports. And the problem is “compounded by poor community awareness and a disjointed approach from the three levels of government.”

28 Jun 2010

Genomic analysis leads to more effective diagnostic tests, treatment options for prostate cancer: Study

A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This first -ever database of its type brings us one step closer to achieving that goal in prostate cancer."

28 Jun 2010

Research roundup: Docs' views of industry gifts; Chemotherapy payments; Health law and states

How Medicare's Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment -- This study examines the impact that Medicare payment cuts for chemotherapy drugs had on treatment for Medicare beneficiaries with newly diagnosed lung cancer, before and after implementation of the June 2005 new payment system, focusing on five chemotherapy drugs "in common use singly or jointly for lung cancer..."

25 Jun 2010

Patient enrollment completed in pilot study of CyPath labeling solution for early detection of lung cancer

Cancer diagnostics company Biomoda, Inc. today announced it completed patient enrollment and sample collection in a pilot study to determine the clinical sensitivity and specificity of its CyPath labeling solution for the early detection of lung cancer. Top-line data and results will be released when available.

25 Jun 2010

Spiration to become a consolidated subsidiary of Olympus

Olympus Corporation is pleased to announce that an agreement was reached with Spiration, Inc. (Head Office: Redmond, Washington, U.S.A; President and CEO: Rick Shea) in which all shares of Spiration® will be acquired by Olympus Corporation of the Americas, a North American subsidiary of Olympus.

From Evident Corporation - Life Sciences 25 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

Cancer forms “intolerable burden” on the community: Health Minister

A new report reveals that here has been a 10 percent rise in cancer figures from 2006 in Australia. The figure translates to nearly 115,000 Australian cancer cases and 43,700 Australians are expected to die from the disease this year.

22 Jun 2010

Biodesix awarded US patent for VeriStrat serum test

Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

ResponseDX: Lung genetic test panel launched to detect EML4-ALK gene variants in lung cancer patients

Celgene signs definitive merger agreement to acquire Abraxis BioScience

New approach to lung cancer measurement holds promise for smokers

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Guidance on ways to protect protect unborn babies from secondhand smoke exposure

Smoking bans in two Minnesota cities not associated with significant economic impact

Asbestos induces cell necrosis, promotes tumor growth

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

Getting rid of asbestos in Australia

Genomic analysis leads to more effective diagnostic tests, treatment options for prostate cancer: Study

Research roundup: Docs' views of industry gifts; Chemotherapy payments; Health law and states

Patient enrollment completed in pilot study of CyPath labeling solution for early detection of lung cancer

Spiration to become a consolidated subsidiary of Olympus

UK cancer survival rates increase at 3% each year

Phase I/II clinical trials show crizotinib reduces lung cancer tumors

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Cancer forms “intolerable burden” on the community: Health Minister

Biodesix awarded US patent for VeriStrat serum test

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

The ultimate guide to lung research tools and protocols eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in